IL23A and psoriasis: Nevertheless, although randomized placebo‐controlled studies are generally regarded as the most reliable way to assess risk, the data from the present study, although indicative, seem to confirm the potential association between the IL‐23 inhibitors risankizumab and tildrakizumab and the occurrence of SARs linked to different types of cancer in patients with psoriasis, and show that this relationship is asymmetrically distributed between women and men according to a gender perspective, with a clear prevalence of oncologic SARs in men.